User profiles for M. Cavassini
 | Matthias CavassiniHead of the Infectious Diseases outpatient clinic, CHUV, Lausanne, Switzerland Verified email at chuv.ch Cited by 31060 |
Long-acting antiretrovirals: a new era for the management and prevention of HIV infection
P Thoueille, E Choong, M Cavassini… - Journal of …, 2022 - academic.oup.com
The long-acting antiretroviral cabotegravir and rilpivirine combination has just received FDA,
EMA and Health Canada approval. This novel drug delivery approach is about to …
EMA and Health Canada approval. This novel drug delivery approach is about to …
[HTML][HTML] Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies
…, S Patterson, S Grabar, C Cazanave, M Cavassini… - The lancet HIV, 2017 - thelancet.com
Background Health care for people living with HIV has improved substantially in the past
two decades. Robust estimates of how these improvements have affected prognosis and life …
two decades. Robust estimates of how these improvements have affected prognosis and life …
Cognitive dysfunction in HIV patients despite long-standing suppression of viremia
S Simioni, M Cavassini, JM Annoni, AR Abraham… - Aids, 2010 - journals.lww.com
Objective: To determine the prevalence of cognitive complaints and HIV-associated
neurocognitive disorders (HANDs) in a cohort of aviremic HIV-positive patients. To evaluate the …
neurocognitive disorders (HANDs) in a cohort of aviremic HIV-positive patients. To evaluate the …
Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study
…, M Battegay, B Hirschel, M Cavassini… - Clinical infectious …, 2011 - academic.oup.com
(See the Editorial Commentary by Saag, on pages 1140–2 .) Background. Patterns of morbidity
and mortality among human immunodeficiency virus (HIV)–infected individuals taking …
and mortality among human immunodeficiency virus (HIV)–infected individuals taking …
Decreasing mortality and changing patterns of causes of death in the S wiss HIV C ohort S tudy
…, A Spörri, H Furrer, M Battegay, M Cavassini… - HIV …, 2013 - Wiley Online Library
Background Mortality among HIV ‐infected persons is decreasing, and causes of death are
changing. Classification of deaths is hampered because of low autopsy rates, frequent …
changing. Classification of deaths is hampered because of low autopsy rates, frequent …
Dominant TNF-α+Mycobacterium tuberculosis–specific CD4+ T cell responses discriminate between latent infection and active disease
…, M Perreau, JM Stalder, LP Nicod, M Cavassini… - Nature medicine, 2011 - nature.com
Rapid diagnosis of active Mycobacterium tuberculosis (Mtb) infection remains a clinical and
laboratory challenge. We have analyzed the cytokine profile (interferon-γ (IFN-γ), tumor …
laboratory challenge. We have analyzed the cytokine profile (interferon-γ (IFN-γ), tumor …
PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals
The mechanisms responsible for the persistence of HIV-1 after many years of suppressive
antiretroviral therapy (ART) have been only partially elucidated. Most of the studies …
antiretroviral therapy (ART) have been only partially elucidated. Most of the studies …
Characteristics, Determinants, and clinical relevance of CD4 T cell recovery to< 500 cells/µL in HIV type 1—infected individuals receiving potent antiretroviral therapy
…, M Opravil, P Vernazza, M Cavassini… - Clinical infectious …, 2005 - academic.oup.com
Background . The CD4 T cell count recovery in human immunodeficiency virus type 1 (HIV-1)—infected
individuals receiving potent antiretroviral therapy (ART) shows high variability. …
individuals receiving potent antiretroviral therapy (ART) shows high variability. …
[HTML][HTML] Changing patterns of cancer incidence in the early-and late-HAART periods: the Swiss HIV Cohort Study
…, L Elzi, H Furrer, A Calmy, M Cavassini… - British journal of …, 2010 - nature.com
Background: The advent of highly active antiretroviral therapy (HAART) in 1996 led to a
decrease in the incidence of Kaposi's sarcoma (KS) and non-Hodgkin's lymphoma (NHL), but …
decrease in the incidence of Kaposi's sarcoma (KS) and non-Hodgkin's lymphoma (NHL), but …
Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV‐infected Individuals
…, H Tegude, S Colombo, M Cavassini… - Clinical …, 2007 - Wiley Online Library
To assess the association of CYP2B6 allelic diversity with efavirenz (EFV) pharmacokinetics,
we performed extensive genotyping of 15 relevant single nucleotide polymorphism in 169 …
we performed extensive genotyping of 15 relevant single nucleotide polymorphism in 169 …